简介:PROMOTIONOFINVITROGROWTHOFHUMANMEDULLOBLASTOMACELLSBYEXOGENEOUSIL-6LiuJiai刘佳;LiHong李宏;HamouMarie-France;NicolasdeTribolet(1Di...
简介:N^6-methyladenosine(m^6A)isanessentialRNAmodificationthatregulateskeycellularprocesses,includingstemcellrenewal,cellulardifferentiation,andresponsetoDNAdamage.Unsurprisingly,aberrantm6Amethylationhasbeenimplicatedinthedevelopmentandmaintenanceofdiversehumancancers.Alteredm6AlevelsaffectRNAprocessing,mRNAdegradation,andtranslationofmRNAsintoproteins,therebydisruptinggeneexpressionregulationandpromotingtumorigenesis.Recentstudieshavereportedthattheabnormalexpressionofm6Aregulatoryenzymesaffectsm6Aabundanceandconsequentlydysregulatestheexpressionoftumorsuppressorgenesandoncogenes,includingMYC,SOCS2,ADAM19,andPTEN.Inthisreview,wediscussthespecificrolesofm6A“writers",“erasers”,and“readers”innormalphysiologyandhowtheiralteredexpressionpromotestumorigenesis.Wealsodescribethepotentialofexploitingtheaberrantexpressionoftheseenzymesforcancerdiagnosis,prognosis,andthedevelopmentofnoveltherapies.
简介:Objective:Toexploretheprobabilityofvascularendothelialgrowthfactor(VEGF)antisenseoligodeoxynucleotidesasadevelopingnewtherapeuticstrategyforglioma.Methods:VEGFproteinexpressionwasdetectedbyS-Pimmunohistochemicaltechnique.TumorcellapoptosiswasobservedbyTUNELmethod.Results:Comparedwithcontrol,VEGFproteinexpressionwasinhibitedbyantisenseoligodeoxynucleotidesinvitro.Andtheinhibitoryeffectsincreasedwiththeincreasingconcentration.VEGFpositiveratewas82.10%incontrolgroup,whilein2.5,5,10(mol/LAODNgroups,theywere70.00%,57.85%,53.20%respectively.Noinhibitioneffectwasfoundinthecelllinestreatedwithmissenseandsenseoligodeoxynucleotides.Invivo,antisenseoligodeoxy-nucleotidestherapyalsoinhibitedVEGFproteinexpressionandinducedtheincreaseofapoptotictumorcells.However,ithasnoeffectontumorcellproliferation.Conclusion:ItishopefulthatVEGFantisenseoligodeoxynucleotidesmaybeanewgenetherapymethodtogliomathroughitsantiangiogenesiseffectbyinhibitionofVEGF.
简介:背景与目的:原发性椎管内淋巴瘤十分罕见,本研究旨在总结原发椎管内淋巴瘤的临床特点,影像学特征及治疗手段,以提高对此病的认识。方法:对北京天坛院神经外科三病房2000年1月至2006年12月间收治的6例经病理证实为椎管内恶性淋巴瘤的患者进行回顾性分析,并文献复习。结果56例患者中,男性4例,女性2例,中位年龄38.5岁。4例患者首发症状为疼痛,平均病程10.9个月。所有患者术前均行MRI检查.肿瘤位于颈段4例,胸段1例,骶段1例。本组患者均采取显微手术治疗,术中辅以电生理监测,肉眼全切1例,近全切除4例,大部分切除1例,无手术死亡。术后4例症状缓解,出院后全部患者均行放射治疗.效果满意。结论:原发性椎管内淋巴瘤是椎管内的罕见肿瘤,缺乏特异性的影像学表现。椎板切除减压,肿瘤切除.术后辅以局部放疗和全身化疗是其主要治疗手段.预后较好。
简介:Objective:Tostudytheroleofconnexingene(Cx43)onthedevelopmentofgliomaandthefeasibilityofusingCx43cDNAasatargetofgenetherapyofgliomas.Methods:ParentalratC6cellsandC6cellstransfectedwithCx43cDNAwereimplantedintorightcaudatenucleusofSDratsascontrolandtransfectedgroup.RatsbearingcerebralC6gliomasweretreatedwithCx43cDNAandemptyvectorastreatedgroupandemptyvectorgroup.Thegeneralmanifestation,survivaltime,MRIdynamicscanningandhistopathologicalchangesofallratswereobserved.Insituhybridizationandimmunohisto-chemistrywereusedforexaminationofCx43mRNAanditsproteiningliomas.AveragenumberofAgNORstainingwasusedfordetectionofcellproliferationactivity,andTUNELmethodfordeterminationofcellapoptosis.Results:Allratsincontrolandemptyvectorgroupdiedofcerebralgliomaswithin3weeksafterimplantationofC6cells.Sixoutofnineratsinthetransfectedgroupandeightoutoftenratsintreatedgroupkeptalivebeyond120dayswithtotallydisappearingofthetumorfoci,exceptonetreatedrathavingalittleresidueoftumor.IngliomasoftransfectedandtreatedgroupsCx43geneexpressionwasupregulated,proliferationactivitywaslowered,However,theapoptoticcellsdidnotincrease.Conclusion:ThepresentstudyindicatesthatCx43geneisofcrucialimportanceinthedevelopmentofmalignantglioma.Itcanbeaneffectivetargetforgenetherapyofgliomas.
简介:Objective:Toinvestigatetheimmunotherapyefficacyoffusioncells(dendritic-C6anti-TGF-β1cells)inthetreatmentofintracranialgliomas.Methods:Dendriticcellswereisolatedfromratbone-marrowprecursorsstimulatedinvitrowithgranulocyte-macrophagecolony-stimulatingfactor(GM-CSF)andInterleukin-4(IL-4).C6anti-TGF-β1cellsoriginallyfromC6celllineofaratglioblastomaweretransfectedwithplasmidofTGF-β1anti-sensegene.FusionsofdendriticcellsandC6anti-TGF-β1cellswerepreparedbypolyethyleneglycol(PEG).TheDC/C6anti-TGF-β1fusioncellswereobservedandconfirmedbylightmicroscopyandscanningelectronmicroscopy.Experimentalratsweredividedintothreegroupsatrandom:C6cells(I),dendritic-C6anti-TGF-β1fusioncellsandC6cells(II)andIMDMmediumonly(III).Thecellswereinjectedintorightparietalloberegionoftheratwithstereotaxictechnique.Histology,tumornecrosisandsurvivaltimewereevaluated.Results:ComparedwiththeratsthatreceivedC6cells(survivalmediantimewaslessthan20days,tumorregionwasseeninallfieldsofobserved),theratsinjectedwithdendritic-C6anti-TGF-β1fusioncellsandC6cellsgotamoreprolongedlifespan(morethan59days),aswellaslesstumorregion(5.01%-6.2%).Therewasnotumornecrosis,butsomegliaswereseeninsurroundings.Allratsweresurvivedandnonecrosiswasobservedinnegativecontrolgroup.StatisticalanalysisshowedthatgroupIIhadsignificantdifferencecomparedwithgroupI.Conclusions:Dendritic-C6anti-TGF-β1fusioncellscouldprolongthelifespanofrats,providingastrategytoachieveanantitumorresponseagainsttumorsinthecentralnervoussystem.
简介:客观:为了与M-CSFR验证MAF-J6-1受体的抗原协会并且进一步学习M-CSF和它的受体的角色,调停了在支持白血病的房间增长的juxtacrine。方法:MAF-J6-1RRE2的Monoclonal抗体(McAb)和rhM-CSFR的polyclonal抗体(PolyAb)被准备。到M-CSFR的McAbRE2的特性被ELISA被间接ELISA,有J6-1房间殖民地形成的跨neutralizing试金和中立化测试证实。结果:到M-CSFR的净化的RE2的反应活动是超过1:16000。M-CSFR和MAF-J6-1R的禁止的活动能被RE2和anti-M-CSFR抗体堵住。到M-CSFR的RE2的反应能被M-CSFR减少。结论:到M-CSFR的RE2的特性被证实,有M-CSFR的MAF-J6-1R的抗原协会被证明。它建议M-CSF和它的受体调停了auto-juxtacrine刺激能是在白血病或nonhematological恶意的起作用的机制。
简介:目的:探讨血管内皮生长因子(VEGF)、CD44v6在非小细胞肺癌(NSCLC)的表达及其临床意义。方法:采用SP免疫组织化学方法观察VEGF、CD44v6在62例NSCLC组织的表达。结果:VEGF、CD44v6在NSCLC组织中表达阳性率分别为72.6%、69.4%,均明显高于癌旁正常组织,P<0.01。VEGF、CD44v6的表达与临床分期及有无淋巴结转移有明显相关,有淋巴结转移组其阳性率明显高于无淋巴结转移组,Ⅲ-Ⅳ期NSCLC组织中VEGF、CD44v6均明显高于Ⅰ-Ⅱ期,P<0.05。VEGF、CD44v6阳性的患者3a生存率均明显低于阴性者,P<0.05。通过COX回归分析发现TNM临床分期、CD44v6阳性表达、有无淋巴结转移及VEGF阳性表达可以作为独立的因素影响NSCLC患者术后的3a生存率。结论:通过这两个指标的检测,可以初步预测NSCLC患者的预后及指导其临床治疗。
简介:目的探讨CD44V6在肠癌组织中的表达及与血管形成的关系。方法应用免疫组化方法检测CD44V6、MVD在57例大肠腺癌、16例腺瘤癌变、62例肠腺瘤及17例正常黏膜中的表达情况并进行分析。结果CD44V6的阳性表达率在腺癌中为45.6%(26/57),腺瘤为58.1%(36/62),腺瘤恶变为75.0%(12/16),正常黏膜为5.9%(1/17);腺癌中MVD值为24.65±7.84。腺癌中CD44V6与MVD的表达有明显的相关性(P〈0.01),而且二者的表达与肿瘤的大小、淋巴结转移、浸润深度与分化程度密切相关。结论CD44V6在肠癌的表达与肿瘤血管形成密切相关,联合检测CD44V6与MVD将有助于筛选具有浸润复发转移的肿瘤,可作为一项辅助指标用于估测预后及指导治疗。
简介:背景与目的:颅内血管外膜细胞瘤(hemangiopericytoma,HPC)发病率低,临床诊治困难,本研究旨在提高对颅内HPC的认识。方法:回顾总结6例颅内HPC患者的临床表现、影像、病理特点以及手术切除和预后情况,并且复习相关文献。结果:6例患者均行开颅手术治疗,其中全切除4例,近全切除2例;术后5例行放射治疗,1例拒绝放疗。术后随访1~10个月,尚未发现肿瘤复发及转移。结论:颅内HPC生长活跃,血供丰富,尤其是位于大脑镰及矢状窦旁时,因此要明确诊断,做好充分的术前准备:手术切除是最佳的治疗手段。应尽量全切,切除范围要广泛.放射治疗是主要的辅助治疗手段。
简介:Asyntheticpolypeptide,pt27,whichisencodedbyacDNAclonewithantloncogeneactivity,p14-6,isfoundtobeabletoreduceremarkablythesoftagarcolonyformationabilityofpartofDTcellsandtoraisetheirresistancetotheouabalntoxtcity.Thisshowsthatthept27peptidecanaffecttheDTcellsInamannersimilartothep14-6doneandprovidesevidencethattherevertingactionofthep14-6toDTcellsmaybeexertedbytheexpressionofitscDNA.
简介:目的探讨Her-2过表达乳腺癌的复发相关因素。方法选取2013年6月至2014年8月镇江市第一人民医院治疗的6例Her-2过表达乳腺癌复发转移患者,分析总结Her-2过表达乳腺癌的复发相关因素及分子生物学行为。结果2例为胸壁局部复发,2例为锁骨上区域淋巴结转移,2例为远处器官转移;所有Her-2过表达复发患者术后病理均提示存在淋巴结转移:1-3枚淋巴结阳性2例;4-9枚淋巴结阳性2例;≥10枚淋巴结阳性2例;Ki-67表达〈15%0例;15%-50%3例,〉50%3例。结论腋窝淋巴结转移状态及Ki-67表达强度是Her-2过表达型乳腺癌复发的重要因素,影响其预后。
简介:背景与目的:鞍区固有的解剖特点使该区肿瘤的切除具有相当大的难度,本文总结和探讨鞍区拟诊生殖细胞瘤诊断性放疗的问题.以避免鞍区生殖细胞瘤的术后并发症。材料和方法:回顾性分析6例拟诊为鞍区生殖细胞瘤的患者行局部野诊断性放疗,放疗采用直线加速器6MV—X线,靶区包括病灶外2cm,常规分割.DT20Gy后复查MRI,根据其结果分别给以继续放疗和手术处理。结果:5例患者病灶明显缩小(1/3以上),症状明显改善,临床诊为生殖细胞瘤,继续全脑全脊髓放疗,4例行顺铂十足叶乙甙化疗,1例行X刀局部推量,5例病灶均消失,随访最长的2年无复发。1例患者病灶变化不大,仅仅中心出现坏死,手术后病理示毛细胞型星形细胞瘤,术后继续放疗。6例患者均临床痊愈,视力恢复正常,无神经功能障碍,双目失明的患者视力恢复,3例治疗前有尿崩的患者治疗后继续服用少量弥凝,其中1位治疗前有垂体功能低下的继续激素替代治疗,其余3位无需服用任何药物。结论:诊断性放疗是安全的,可作为拒绝或难以耐受手术的鞍区拟诊生殖细胞瘤的选择之一。
简介:p90核糖体S6蛋白激酶(rihosomalS6kinase,RSK)为Ras信号转导通路下游途径的重要调控因子,对Ras通路起调控作用。近年发现RSK家族与恶性肿瘤发生、发展密切相关。本文就RSK家族与恶性肿瘤的关系作简要综述。